Literature DB >> 2289552

CO transfer capacity as a determining factor of survival for severe hypoxaemic COPD patients under long-term oxygen therapy.

P Dubois1, J Machiels, F Smeets, J P Delwiche, J Lulling.   

Abstract

The transfer capacity for carbon monoxide is a commonly used method in clinical practice but is rarely considered as a prognostic factor for patients under long term oxygen therapy (LTOT). LTOT was applied to 217 stable, severely hypoxaemic (arterial oxygen tension (PaO2 less than 7.3 kPa or 55 mmHg) chronic obstructive pulmonary disease (COPD) patients, according to the usual recommendations. The average survival rate of this series is rather poor: 46% at 24 months. There is nevertheless an important difference between patients with a normal transfer coefficient and those with a decreased one (79% survival at 2 yrs as compared to 37%). On the other hand, the degree of airflow limitation has no prognostic value in the present series of very disabled patients. We can conclude that hypoxaemic COPD patients with a severely decreased transfer coefficient have a poor prognosis, even under LTOT, compared to patients with an equivalent impairment of airflow limitation and hypoxaemia but with a normal CO transfer factor/alveolar ventilation ratio (TLCO/VA).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2289552

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  2 in total

1.  Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD.

Authors:  Aparna Balasubramanian; Todd M Kolb; Rachel L Damico; Paul M Hassoun; Meredith C McCormack; Stephen C Mathai
Journal:  Chest       Date:  2020-03-14       Impact factor: 9.410

2.  Lung function indices for predicting mortality in COPD.

Authors:  Afroditi K Boutou; Dinesh Shrikrishna; Rebecca J Tanner; Cayley Smith; Julia L Kelly; Simon P Ward; Michael I Polkey; Nicholas S Hopkinson
Journal:  Eur Respir J       Date:  2013-01-24       Impact factor: 16.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.